BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22005044)

  • 1. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
    Burashnikov A; Belardinelli L; Antzelevitch C
    J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
    Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
    Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
    Burashnikov A; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):400-8. PubMed ID: 22322366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.
    Sicouri S; Burashnikov A; Belardinelli L; Antzelevitch C
    Circ Arrhythm Electrophysiol; 2010 Feb; 3(1):88-95. PubMed ID: 19952329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
    Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
    J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
    Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
    J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
    Kumar K; Nearing BD; Carvas M; Nascimento BC; Acar M; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):796-802. PubMed ID: 19298570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
    Burashnikov A; Sicouri S; Di Diego JM; Belardinelli L; Antzelevitch C
    J Am Coll Cardiol; 2010 Oct; 56(15):1216-24. PubMed ID: 20883928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.
    Burashnikov A; Petroski A; Hu D; Barajas-Martinez H; Antzelevitch C
    Heart Rhythm; 2012 Jan; 9(1):125-31. PubMed ID: 21884675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
    Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
    Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
    Burashnikov A; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.
    Sicouri S; Glass A; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2008 Jul; 5(7):1019-26. PubMed ID: 18598958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
    Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
    Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.
    Aidonidis I; Doulas K; Hatziefthimiou A; Tagarakis G; Simopoulos V; Rizos I; Tsilimingas N; Molyvdas PA
    J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):94-101. PubMed ID: 22872232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
    Chandra P; Rosen TS; Yeom ZH; Lee K; Kim HY; Danilo P; Rosen MR
    Europace; 2004 Sep; 6(5):384-91. PubMed ID: 15294262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of I
    Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial-selective sodium channel blockers: do they exist?
    Burashnikov A; Antzelevitch C
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
    Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
    Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.